Upadacitinib increases time spent with improved AD-related symptoms
26 Mar 2024
byElaine Soliven
Treatment with upadacitinib, an oral selective Janus kinase inhibitor, led to greater proportions of days spent with improved nighttime itch and sleep disturbance experienced by patients with moderate-to-severe atopic dermatitis (AD), according to an integrated analysis of the phase III Measure Up 1 and 2 studies presented at AAD 2024.
